179 related articles for article (PubMed ID: 37353806)
1. Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network.
Nigon E; Lefeuvre-Plesse C; Martinez A; Chauleur C; Lortholary A; Favier L; Bats AS; Guille A; AdélaÏde J; Finetti P; de Casteljac V; Provansal M; Mamessier E; Bertucci F; Ray-Coquard I; Sabatier R
J Transl Med; 2023 Jun; 21(1):408. PubMed ID: 37353806
[TBL] [Abstract][Full Text] [Related]
2. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
[TBL] [Abstract][Full Text] [Related]
3. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
4. Uterine papillary serous and clear cell carcinomas: Comparison of characteristics and clinical outcomes.
Yuce Sari S; Guler OC; Oymak E; Gultekin M; Yigit E; Kahvecioglu A; Yuce K; Celik H; Usubutun A; Bolat F; Onal C; Yildiz F
J Obstet Gynaecol Res; 2022 Jul; 48(7):1876-1887. PubMed ID: 35385171
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic Significance of HNF-1β, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
Ye S; Yang J; You Y; Cao D; Huang H; Wu M; Chen J; Lang J; Shen K
Medicine (Baltimore); 2016 Mar; 95(9):e3003. PubMed ID: 26945423
[TBL] [Abstract][Full Text] [Related]
6. Should endometrial clear cell carcinoma be classified as Type II endometrial carcinoma?
Bae HS; Kim H; Young Kwon S; Kim KR; Song JY; Kim I
Int J Gynecol Pathol; 2015 Jan; 34(1):74-84. PubMed ID: 25473756
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network.
Romeo C; Le Saux O; Jacobs M; Joly F; Ferron G; Favier L; Fumet JD; Isambert N; Colombo PE; Sabatier R; Bastide L; Charreton A; Devouassoux-Shisheboran M; Gertych W; Dubot C; Bello Roufai D; Bataillon G; Berton D; Kalbacher E; Pautier P; Pomel C; Cornou C; Treilleux I; Lardy-Cleaud A; Ray-Coquard I
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053517
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
[TBL] [Abstract][Full Text] [Related]
9. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
Sood BM; Jones J; Gupta S; Khabele D; Guha C; Runowicz C; Goldberg G; Fields A; Anderson P; Vikram B
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):208-16. PubMed ID: 12909235
[TBL] [Abstract][Full Text] [Related]
10. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
McIntyre JB; Wu JS; Craighead PS; Phan T; Köbel M; Lees-Miller SP; Ghatage P; Magliocco AM; Doll CM
Gynecol Oncol; 2013 Mar; 128(3):409-14. PubMed ID: 23266353
[TBL] [Abstract][Full Text] [Related]
12. The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
Lenck C; Chopin N; Gouy S; Bonsang-Kitzis H; Martinez-Gomez C; Radosevic-Robin N; Martin S; Lefeuvre-Plesse C; Lambaudie E; Leblanc E; Guyon F; Classe JM; Ramanah R; Beurrier F; Angeles MA; Pomel C; Joly F; de la Motte Rouge T; Provansal M; Lesoin A; Floquet A; Berton D; Kalbacher E; Chakiba C; Meeus P; Selle F; Treilleux I; Lecuru F; Pautier P; Ray-Coquard I
Gynecol Oncol; 2020 Apr; 157(1):78-84. PubMed ID: 32131977
[TBL] [Abstract][Full Text] [Related]
13. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
14. Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
Catasus L; D'Angelo E; Pons C; Espinosa I; Prat J
Mod Pathol; 2010 May; 23(5):694-702. PubMed ID: 20173732
[TBL] [Abstract][Full Text] [Related]
15. [Clinical analysis of 32 cases with neuroendocrine carcinoma of the uterine cervix in early-stage disease].
Wang Z; Wu L; Yao H; Sun Y; Li X; Li B; Zhang R; Ma S; Huang M
Zhonghua Fu Chan Ke Za Zhi; 2015 Mar; 50(3):198-203. PubMed ID: 26268410
[TBL] [Abstract][Full Text] [Related]
16. Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The Cancer Genome Atlas-like Prognostic Subgroups.
Irshaid L; Costigan DC; Dong F; Matulonis UA; Nucci MR; Kolin DL
Mod Pathol; 2023 May; 36(5):100123. PubMed ID: 36857998
[TBL] [Abstract][Full Text] [Related]
17. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
18. The role of adjuvant treatment for early-stage uterine clear cell carcinomas.
Orellana TJ; Garrett AA; Soong TR; Rives T; Courtney-Brooks M; Taylor SE; Lesnock J; Berger J; Boisen M; Coffman L; Buckanovich R; Mahdi H; Comerci JC; Beriwal S; Sukumvanich P; Edwards RP; Bhargava R; Olawaiye AB
Gynecol Oncol; 2023 Mar; 170():77-83. PubMed ID: 36641903
[TBL] [Abstract][Full Text] [Related]
19. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
